press releases
11 SEPTEMBER 2024: Synerkine Pharma receives European Orphan Drug Designation for SK-01 to treat CRPS
Synerkine Pharma today announced that the European Commission has granted the Orphan Drug Designation (ODD) for SK-01, the company’s most advanced development program, to treat complex regional pain syndrome (CRPS). Synerkine is progressing steadily toward the initiation of the first clinical study with SK-01 in CRPS and is currently manufacturing clinical-grade material.
READ MORE
19 FEBRUARY 2024: Synerkine Pharma and NorthX Biologics sign manufacturing alliance
Synerkine Pharma today announced a manufacturing alliance with NorthX Biologics AB, a leading biopharmaceutical company committed to pioneering solutions in gene therapy and biotechnology. The alliance will support Synerkine’s development portfolio, including its most advanced program SK-01, a cytokine-cytokine fusion protein combining the effects of IL-4 and IL-10 as a treatment option for chronic pain.
READ MORE
25 JANUARY 2024: Synerkine Pharma appoints Industry Veteran Anders Ekblom to its Board of Directors
Synerkine Pharma today announced the appointment of industry veteran Anders Ekblom, MD, PhD, DDS as a new Member of its Board of Directors. The appointment of Dr. Ekblom adds a wealth of pharmaceutical industry and drug development expertise to Synerkine Pharma’s board combined with his scientific knowledge of pain physiology and the implications of pain in various disease settings and markets.
READ MORE
12 OCTOBER 2023: Synerkine Pharma secures EUR 12.1 million to accelerate novel pain therapeutics towards clinical proof-of-concept
Synerkine Pharma today announced an extension of its Series A financing led by Flerie with support from new investors, InnovationQuarter Capital and Utrecht Health Seed Fund, and existing investor Thuja Capital. The equity financing is accompanied by a matching innovation credit from Rijksdienst voor Ondernemend (RVO) Nederland - the Netherlands Enterprise Agency.
READ MORE
16 DECEMBER 2021: SYNERKINE PHARMA RAISES € 3.5 MILLION IN AN EXTENDED SERIES A FINANCING
Synerkine Pharma today announced that it has added EUR 3.5 million to its Series A funding. The extension was led by Flerie with support from existing investors Thuja Capital and Utrecht Holdings.
READ MORE
25 MARCH 2019: SYNERKINE PHARMA RAISES € 3.3 MILLION IN SERIES A FINANCING
Synerkine Pharma today announced that it successfully closed a EUR 3.3 million Series A financing from Thuja Capital, an undisclosed private investor, and the company’s founders.
READ MORE